Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
about
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialRecent advancements of bortezomib in acute lymphocytic leukemia treatmentPrognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunctionTargeting the phosphoinositide 3-kinase pathway in hematologic malignanciesBAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia.Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemiaCell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenograftsPharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoCharacterization of CD22 expression in acute lymphoblastic leukemiaVandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Race/ethnicity moderates the effect of prepartum menthol cigarette use on postpartum smoking abstinence.Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.Improving access to novel agents for childhood leukemia.Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupOutcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remissionOutcomes after induction failure in childhood acute lymphoblastic leukemia.Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy.Type D personality parents of children with leukemia tend to experience anxiety: the mediating effects of social support and coping style.Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.Natural killer cell therapy in children with relapsed leukemia.Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.Psychological Impact of Chemotherapy for Childhood Acute Lymphoblastic Leukemia on Patients and Their Parents.Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.Chimeric Antigen Receptor T-Cell Therapy for the Community OncologistProtein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective reviewPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationImproving outcomes for high-risk ALL: translating new discoveries into clinical care.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Genomics in acute lymphoblastic leukaemia: insights and treatment implications.Emerging kinase inhibitors of the treatment of gastric cancer.Twist as a new prognostic marker in hematological malignancies.Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.
P2860
Q24621523-3FAB61AA-B8F2-4575-BBA8-91214DE7D62BQ26829613-99B03E0E-CA67-4795-B4C9-4CC52AA2D708Q27851831-3E91BBC1-1ADB-4A56-92E9-5E45976543FEQ28276513-7A5482EA-9DCF-418C-AAC0-01F5979C447BQ33558141-AD4ABC6C-63E8-4EB9-BAD1-653A3A45CF05Q34053504-9D037AD1-2939-451C-8EC5-40C2CB4C6C8AQ34131813-A2F04C9D-C5B5-4BB3-B2A9-F8A3E0A14A84Q34135333-0964F1F0-1584-4B93-809B-04E571ACA98BQ34221738-1E9D3A07-406B-41E6-90C6-459795832782Q34547528-3B3742BC-6ED4-4D44-A8A3-263EC97E6B5CQ35514128-A8FA18FF-7702-4AC7-B8F9-042AE3314A1EQ35569079-54970857-CAFA-4246-A249-2DD6CA32BB07Q35571763-8AA9B0A0-3772-4471-BDB4-066B8955286EQ35646066-5D715D4A-F048-46FA-A349-BE1E6C7CDE96Q35688742-F0E6B8C7-CD91-434B-B959-EB00CB912113Q35953635-254E01A5-22CF-4926-A482-8D493DF13349Q36023505-8189C162-2F74-476E-A15C-C1644BA40348Q36029619-A56A8EAC-A986-44AD-BEC8-F60049FE76FCQ36134458-29ADCEFB-4FA2-44AA-BBAA-2AFDDA1AFBE9Q36150960-D8FC5132-8D9F-4273-8B9F-C7B5C9AA6E99Q36161733-B2B01FC4-AEC7-46B4-8161-09634D4BBEC3Q36251948-DA695E27-4EFE-4AB5-B273-45B8728ABCCFQ36302281-E975A8DF-A0A9-4990-B1CC-8B918330D987Q36421001-4AC1410C-245D-41AE-8F7F-F7973593D13AQ36488188-55962D6D-4F68-4AEA-BE1E-5267B30DA576Q36689775-2524A17F-7DB4-4BF3-9F86-A09264362CE6Q36731638-4CCDBDF6-C70C-4CA4-99C5-A48B2F772E2CQ36738818-F40E2860-7AF9-4F33-BA72-86DEA78FFE3BQ36884399-3FB6DB1B-08BD-46F8-A335-8FBB7595DE28Q36917916-2BEBDF6F-7A4D-4C13-9DE0-50E35DFF095FQ36957835-175298F0-B10D-49C2-AF7B-BF2A86D827FBQ37233236-74A7A9C6-684C-4679-B836-0D8AD7EF8D28Q37524180-67278168-3B05-4962-B378-478FDBF9F735Q37676956-CA6FBB4C-DECD-4F80-976A-CB647A3E775AQ37849259-48730F98-A5C7-4F55-AEE7-4EBC8FF6427FQ38097334-E9D25A09-98A9-4EC6-979D-0DC15024F86CQ38381463-9D172743-4D85-49AA-BC62-BFFB3D06EB09Q38506084-C13BCC28-2913-46C2-8CBC-4917E894E315Q38552664-B86CC211-77BE-47D5-AD5D-90BFD7BDE04EQ38669037-269AB33E-D868-4A75-905C-B579AF7657DC
P2860
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@ast
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@en
type
label
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@ast
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@en
prefLabel
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@ast
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@en
P2093
P2860
P356
P1476
Outcome of patients treated fo ...... ood Leukemia Consortium study.
@en
P2093
Bruce Bostrom
Clare J Twist
Elena Eckroth
Elizabeth Raetz
Lingyun Ji
Mignon L Loh
Phillip Barnette
Raymond Hutchinson
Richard H Ko
Richard Sposto
P2860
P304
P356
10.1200/JCO.2009.22.2950
P407
P577
2009-10-19T00:00:00Z